Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
2541-2560 of 3,900 trials

Pseudomyxoma Peritonei: Neoadjuvant Chemotherapy Study

We are studying whether a combination of capecitabine and cyclophosphamide can help patients with large Pseudomyxoma peritonei before surgery. The goal is to see if this treatment improves tumor shrinkage and surgical success.

Pseudomyxoma Peritonei>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Ocular Melanoma: Roginolisib Treatment Study

We are studying the effectiveness of roginolisib for patients with advanced ocular or uveal melanoma compared to standard therapies. The trial will also assess safety and quality of life impacts.

Uveal MelanomaEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncologyOphthalmology

Acute Myeloid Leukemia: JNJ-90189892 Treatment

We are testing a new medication for patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasms. The study aims to determine the safest dose and gather initial information on its effects.

Relapsed or Refractory Acute Myeloid Leukemia>2 yearsSafety phase (I)HematologyOncology

Burn Patients: Antibiotic Use Before Surgery

We are studying whether giving antibiotics before skin graft surgery helps reduce infections and complications in burn patients. This research may provide insights into improving recovery and hospital stays.

Burn Injury>2 yearsConfirmation phase (III)Standard MedicinesPartially RemoteInfectious DiseasesOrthopedics and Traumatology

PRCA Treatment: Isatuximab Study

We are studying whether the drug isatuximab can help patients with pure red cell aplasia after stem cell transplantation. This trial compares its effects to standard supportive care to see which is more effective.

Pure Red Cell Aplasia>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Idiopathic Retroperitoneal Fibrosis: Early Steroid Discontinuation Study

We are investigating whether stopping steroid treatment early in patients with idiopathic retroperitoneal fibrosis affects relapse rates. This study aims to improve treatment strategies for managing this condition.

Idiopathic Retroperitoneal Fibrosis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Systemic Lupus Erythematosus: Cenerimod Study

We are examining the long-term safety and tolerability of cenerimod in adults with systemic lupus erythematosus. This study looks at how the medication works alongside existing treatments.

Systemic Lupus Erythematosus>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology

Diabetic Macular Edema: Dexamethasone Implant Study

We are investigating a new treatment using a dexamethasone implant for patients with diabetic macular edema. The goal is to see if it improves vision and how well patients tolerate the treatment.

Diabetic Macular Oedema>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesEndocrinologyOphthalmology

Candidiasis Treatment: Mecloderm® Cream Study

We are comparing a new cream to standard treatments and a placebo for patients with moderate to severe skin candidiasis. The goal is to see which option works best for reducing inflammation and discomfort.

Skin and Nail Candidiasis>2 yearsConfirmation phase (III)Dermatology

Breast Cancer: Patritumab Deruxtecan with Pembrolizumab

We are studying a new treatment combination for high-risk early-stage breast cancer patients to see if it improves tumor response compared to standard chemotherapy. This trial will help us understand the safety and effectiveness of this new approach.

Triple Negative Breast Cancer1-2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

PBP1510 for Advanced Pancreatic Cancer

We are studying a new treatment called PBP1510 in patients with advanced pancreatic cancer that has not responded to previous chemotherapy. The trial will evaluate its safety and effectiveness, both alone and with another drug, gemcitabine.

Advanced Pancreatic CancerSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Short-Term Insomnia: Neurexan® Treatment

We are exploring whether Neurexan® can improve sleep quality and daytime performance in people with short-term insomnia. This study compares its effects to a placebo to understand its potential benefits.

Short-Term Insomnia>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteNeurologyPsychiatry

Kidney Transplant: Regulatory T Cell Therapy

We are studying the safety of using regulatory T cells in kidney transplant recipients to see if it helps the body accept the new kidney better. This may allow for less reliance on standard immunosuppressive medications.

Kidney TransplantationSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteInternal MedicineNephrology

Chronic Immune Thrombocytopenia: Mezagitamab Injection

We are studying a new injection, mezagitamab, for adults with chronic immune thrombocytopenia to see if it can improve platelet counts and reduce symptoms compared to a placebo.

Primary Immune Thrombocytopenia6-12 monthsConfirmation phase (III)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementHematology

Ileal Crohn’s Disease: AZD7798 Study

We are testing the safety and effectiveness of AZD7798 in adults with ileal Crohn’s disease who have an ileostomy. This study aims to see how well the treatment helps with healing and managing symptoms.

Crohn's Disease1-2 yearsEfficacy phase (II)16-20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterologyInternal Medicine

Neovascular AMD: Faricimab Treatment Study

We are exploring whether two initial doses of faricimab can help keep neovascular AMD inactive in treatment-naive patients. The study also looks at factors that may predict disease activity and recurrence.

Age-related Macular Degeneration>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesOphthalmology

Nivolumab and Entinostat for High-Risk Cancers in Kids

We are exploring a new treatment combining Nivolumab and Entinostat for children and adolescents with hard-to-treat cancers. The study aims to see if this combination can help those with specific tumor characteristics.

Relapsed or Refractory High-Risk Malignant Disease>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOncologyPediatrics

HPV16-Related Throat Cancer: FluBHPVE6E7 Immunotherapy

We are testing a new immunotherapy for patients with HPV16-associated oropharyngeal squamous cell carcinoma. The goal is to evaluate its safety and how well it works in treating this type of cancer.

Human Papilloma Virus InfectionSafety phase (I)OncologyOtolaryngology

Heart Health: Apixaban vs. Warfarin Study

We are comparing two medications to see which is more effective in resolving blood clots in patients with left ventricular thrombus after a heart attack. We're also looking at safety and bleeding risks associated with each treatment.

Acute Myocardial InfarctionLeft Ventricular Thrombosis3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteCardiologyInternal Medicine

Metastatic Colorectal Cancer: Valproic Acid and Standard Treatment

We are studying a new combination of Valproic acid with standard therapies for patients with metastatic colorectal cancer who have already been treated. The goal is to see if this combination improves survival and quality of life compared to standard treatment alone.

Metastatic Colorectal Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesGastroenterologyOncology